Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir in Pediatric Chronic HCV
NCT03022981Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2017
- Primary completion
- Nov 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Jan 2017; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03022981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022981.